23 MARCH 2006

NEW ZEALAND GAZETTE, No. 27

(i) Māori organisations;
(ii) organisations representing industry and
commerce;
(iii) organisations representing community entities
(including the Regional, City and District
Councils);
(iv) organisations representing health, education
and community services.

(j) Up to two members co-opted by the Waikato
Institute of Technology Council as and when it sees
fit.

4. The term of office of members of the council,
   vacation of office, disclosure of members’ interest and
   casual vacancies are covered in sections 173 to 176 of
   the Education Act 1989.
   Subject to section 173, the maximum term for any member,
   other than the chief executive officer, shall be three
   consecutive four-year terms.

5. The powers of the Waikato Institute of Technology
   Council shall not be affected by the amendments made by
   this notice or by vacancy in the membership thereof.
   Dated at Wellington this 23rd day of February 2006.

DR MICHAEL CULLEN, Minister for Tertiary Education.

go1871

Private Schools Conditional Integration
Act 1975

Supplementary Integration Agreement

Pursuant to section 10 of the Private Schools Conditional
Integration Act 1975, notice is given that a supplementary
integration agreement has been signed between the Minister
of Education on behalf of Her Majesty the Queen, acting
through the Senior Manager, National Operations, Ministry
of Education, pursuant to delegated authority, and the
proprietor of the following school:

St Bernadette’s School, Hornby, Christchurch.

The said supplementary integration agreement was executed
on 15 March 2006.

A copy of the supplementary integration agreement is
available for inspection without charge by any member of
the public at the local office of the Ministry of Education,
123 Victoria Street, Christchurch.

Dated at Wellington this 15th day of March 2006.

JIM MATHESON, Acting Senior Manager, National
Operations.

go1751

Health

Medicines Act 1981

Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Product:
Tarceva

Active Ingredient:
Erlotinib hydrochloride 109.29mg equivalent to erlotinib 100mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Roche Products (New Zealand) Limited

Manufacturers:
F Hoffmann-La Roche AG, Basel, Switzerland
Schwarz Pharma Manufacturing Inc, Seymour, Indiana, United States of America

Note: This consent is valid for two years from the date of publication of this notice.

Product:
Tarceva

Active Ingredient:
Erlotinib hydrochloride 163.93mg equivalent to erlotinib 150mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Roche Products (New Zealand) Limited

Manufacturers:
F Hoffmann-La Roche AG, Basel, Switzerland
Schwarz Pharma Manufacturing Inc, Seymour, Indiana, United States of America

Note: This consent is valid for two years from the date of publication of this notice.

Product:
Tarceva

Active Ingredient:
Erlotinib hydrochloride 27.32mg equivalent to erlotinib 25mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Roche Products (New Zealand) Limited

Manufacturers:
F Hoffmann-La Roche AG, Grenzacherstrasse 124, Basel, Switzerland
Schwarz Pharma Manufacturing Inc, Seymour, Indiana, United States of America

Note: This consent is valid for two years from the date of publication of this notice.

Dated this 18th day of March 2006.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go1859